How much does Pexidartinib cost?

In August 2019, the U.S. Food and Drug Administration (FDA) approved pexidartinib , the first systemic treatment option for adult patients with symptomatic tenosynovial giant cell tumors who have severe morbidity or functional limitations that cannot be improved with surgery. Tenosynovial giant cell tumor is a rare proliferative tumor that arises in the synovium, bursa, or tendon sheath due to overproduction of colony-stimulating factor 1. Historically, treatment options for patients with localized or diffuse giant cell tumors of the tenosynovium have been limited to surgery.

However, for some patients, surgical resection worsens functional limitations and/or morbidity. Pexidartinib, an oral tyrosine kinase inhibitor that selectively inhibits the colony-stimulating factor 1 receptor, is the first systemic treatment to demonstrate a significant improvement in overall response rate compared with placebo. Clinicians using pesidartinib should monitor for liver-related adverse events, which may require treatment interruption, dose reduction, or discontinuation of treatment. Pesidartinib offers a new non-surgical treatment option for patients with tenosynovial giant cell tumors that can significantly improve patients' overall response, range of motion, physical function, tumor volume and stiffness.

About pexidartinib Common side effects are an increase in lactate dehydrogenase (a protein that helps the body produce energy), an increase in aspartate aminotransferase (an enzyme found mainly in the liver but also in muscles), loss of hair color, an increase in alanine aminotransferase (an enzyme found mainly in the liver and kidneys), and an increase in cholesterol.

Pesidartinib is not marketed in the country. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.